Drug Trial Radar · NCT00654901
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Last checked: Nov 20, 2026Latest source record: May 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
881
Actual
Start
Mar 2008
Primary completion
May 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 15 months, up to 18 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity * To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP\~T or Infanrix hexa™. * To describe the immunogenicity of a booster dose of DTaP-IPV-HepB-PRP\~T in a subset of subjects. Safety \- To describe the safety profile after a booster dose of DTacP-IPV-HepB-PRP\~T.
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection
Interventions
DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)Biological
0.5 mL, Intramuscular
DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)Biological
0.5 mL, Intramuscular
DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)Biological
0.5 mL, Intramuscular
Infanrix Hexa™Biological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~TTime frame: Day 0 (pre-booster) and Day 30 (one month post-booster)
- Number of Participants With Antibody Persistence Before and Immunogenicity Response After Booster Vaccination With DTaP-IPV-Hep B-PRP~T VaccineTime frame: Day 0 (pre-booster) and Day 30 (one month post-booster)
- Number of Participants With Solicited Injection Site or Systemic Reactions After Vaccination With DTaP-IPV-Hep B-PRP~T VaccineTime frame: Days 0 up to 7 after any injection
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Estado de México, Mexico
Site not named
Insurgentes Cuicuilco, Mexico
Site not named
Monterrey, Mexico
Site not named
Puebla City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.